Sponsors
Gold Sponsors
McKenna Long & Aldridge LLP (MLA) is an international law firm with 475 attorneys and
public policy advisors. The firm provides business solutions in the areas of environmental
regulation, international law, public policy and regulatory affairs, corporate law, government
contracts, intellectual property and technology, complex litigation, real estate, energy and
finance. MLA’s Life Sciences and Public Health Preparedness practice is a multi-faceted
resource for the biotechnology sector, including experience in emerging infectious diseases,
biodefense, pandemic influenza preparedness, detection and diagnostic technologies, decision
support systems for public health response, industrial biotechnology, and the burgeoning
clean-tech sector. For more information, visit www.mckennalong.com
For more information, visit www.mckennalong.com/.
Silver Sponsors
Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies. CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on the company’s extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs. Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.
For more information, visit www.chimerix-inc.com/.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.
For more information, visit www.emergentbiosolutions.com/.
GenPhar, Inc. is a biopharmaceutical company dedicated to providing vaccines that protect against infectious diseases with great socio-economic impacts worldwide.
For more information, visit www.genphar.com/.
MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca PLC.
For more information, visit www.medimmune.com.
The development of effective countermeasures to a range of potential biological and chemical weapons is PharmAthene’s primary objective. PharmAthene has recruited exceptional scientists and management to lead its programs and oversee the outsourcing of various program activities with an urgency to develop these countermeasures as rapidly as possible. In any organization, it is the people who make it all happen and that is especially true at PharmAthene. We have a unique group of seasoned, talented pharmaceutical and biotechnology professionals—each an expert in his or her respective field. Ranging from expertise in infectious diseases and genome science across the spectrum to pharmaceutical marketing and management, the depth of knowledge and collective accomplishments of our PharmAthene team is extremely impressive.
For more information, visit www.pharmathene.com/.
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Year after year we help develop or commercialize every one of the world’s top 30 best selling drugs.
For more information, visit www.quintiles.com.
VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy. Using the TLR technology, vaccines can be produced by simple, low-cost, highly-scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture influenza vaccine production. VaxInnate's technology has the potential to significantly improve the cost-effectiveness, manufacturing capacity, and potency of influenza vaccines - key issues facing the clinical and public health communities.
VaxInnate has a BSL2+ laboratory operational within the Cranbury site, and also has access to BSL-2 vivarium space through a collaborative research agreement with Yale University . VaxInnate also has a collaborative arrangement with an academic institution for access to high level biocontainment facilities (BSL-3 and -4). Since avian influenza requires BSL-3 or -4 facilities, depending on the strain in question, this access enables the VaxInnate to conduct live virus challenges in animal models.
For more information, visit www.vaxinnate.com.
Bronze Sponsors
Accelovance Inc., headquartered in Rockville, MD, has a proven approach
to accelerating clinical development that delivers study Sponsors optimal
results through greater control and productivity. Our staff performance,
predictable enrollment, and executive focus produce cost- effective
solutions to address our clients’ needs as they define them.
For more information, visit www.accelovance.com/.
Lovelace Respiratory Research Institute offers extensive ABSL-3 animal exposure facilities for collaborative or contract work with qualified entities. In addition, the Institution offers extensive facilities, infrastructure, and trained professional staffing for aerosol science work, respiratory and cardiovascular physiology and exposure studies, and infectious disease research to those individuals or organizations that have or are seeking federal or other funding for CBRN terrorism studies.
For more information, visit www.lrri.org/.
Skyline Integrated Technology Enterprises (SITE), a woman-owned small business, is an outgrowth of Kalman & Company, Inc. SITE leverages Kalman’s over twenty years experience in providing program management, acquisition, business and analytical services. Our experienced professionals provide integrated consulting services in the areas of project and contract management, proposal writing, and government cost accounting practices to companies seeking contracts with the Federal Government and those seeking general business management solutions.
For more information, visit www.skylineitent.com.